• +1-646-491-9876
    • +91-20-67278686

    Search

    Ornithine-Transcarbamylase Deficiency-Pipeline Review H1 2017

    Ornithine-Transcarbamylase Deficiency-Pipeline Review H1 2017

    • Report Code ID: RW0001834399
    • Category Pharmaceuticals
    • No. of Pages 40
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Ornithine-Transcarbamylase Deficiency - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Ornithine-Transcarbamylase Deficiency - Pipeline Review, H1 2017, provides an overview of the Ornithine-Transcarbamylase Deficiency (Genetic Disorders) pipeline landscape.

    Ornithine transcarbamylase (OTC) deficiency is a rare X-linked genetic disorder characterized by complete or partial lack of the enzyme ornithine transcarbamylase (OTC) . OTC plays an important role in the break down and removal of nitrogen the body (urea cycle) . The lack of the OTC enzyme results in excessive accumulation of nitrogen, in the form of ammonia (hyperammonemia) , in the blood. Symptoms include vomiting, refusal to eat, progressive lethargy, and coma. Treatment includes nitrogen scavenging agents.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Ornithine-Transcarbamylase Deficiency - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ornithine-Transcarbamylase Deficiency (Genetic Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Ornithine-Transcarbamylase Deficiency (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ornithine-Transcarbamylase Deficiency and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II and Preclinical stages are 1, 1, 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Ornithine-Transcarbamylase Deficiency (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Ornithine-Transcarbamylase Deficiency (Genetic Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Ornithine-Transcarbamylase Deficiency (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Ornithine-Transcarbamylase Deficiency (Genetic Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Ornithine-Transcarbamylase Deficiency (Genetic Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Ornithine-Transcarbamylase Deficiency (Genetic Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Ornithine-Transcarbamylase Deficiency (Genetic Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Ornithine-Transcarbamylase Deficiency (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Ornithine-Transcarbamylase Deficiency - Overview
    Ornithine-Transcarbamylase Deficiency - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Ornithine-Transcarbamylase Deficiency - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Ornithine-Transcarbamylase Deficiency - Companies Involved in Therapeutics Development
    Dimension Therapeutics Inc
    Lucane Pharma SA
    PhaseRx Inc
    Promethera Biosciences SA
    RaNA Therapeutics Inc
    Selecta Biosciences Inc
    Unicyte AG
    Ornithine-Transcarbamylase Deficiency - Drug Profiles
    DTX-301 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy to Activate Ornithine Transcarbamylase for Ornithine Transcarbamylase Deficiency - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy to Activate Ornithine Transcarbamylase for Ornithine Transcarbamylase Deficiency - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Heparesc - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HepaStem - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PRX-OTC - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SHP-641 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sodium benzoate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stem Cell Therapy for Type 1 Diabetes, Urea Cycle Disorders and Acute Liver Failure - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Ornithine-Transcarbamylase Deficiency - Dormant Projects
    Ornithine-Transcarbamylase Deficiency - Product Development Milestones
    Featured News & Press Releases
    May 03, 2017: PhaseRx to Present Data at the American Society of Gene & Cell Therapy 20th Annual Meeting
    Apr 25, 2017: PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-OTC from European Medicines Agency
    Feb 08, 2017: PhaseRx to Present Data for PRX-OTC at the 13th Annual WORLDSymposium 2017
    Nov 28, 2016: PhaseRx Receives Orphan Drug Designation from FDA for PRX-OTC for the Treatment of Ornithine Transcarbamylase Deficiency
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Ornithine-Transcarbamylase Deficiency, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Ornithine-Transcarbamylase Deficiency - Pipeline by Dimension Therapeutics Inc, H1 2017
    Ornithine-Transcarbamylase Deficiency - Pipeline by Lucane Pharma SA, H1 2017
    Ornithine-Transcarbamylase Deficiency - Pipeline by PhaseRx Inc, H1 2017
    Ornithine-Transcarbamylase Deficiency - Pipeline by Promethera Biosciences SA, H1 2017
    Ornithine-Transcarbamylase Deficiency - Pipeline by RaNA Therapeutics Inc, H1 2017
    Ornithine-Transcarbamylase Deficiency - Pipeline by Selecta Biosciences Inc, H1 2017
    Ornithine-Transcarbamylase Deficiency - Pipeline by Unicyte AG, H1 2017
    Ornithine-Transcarbamylase Deficiency - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Ornithine-Transcarbamylase Deficiency, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Dimension Therapeutics Inc
    Lucane Pharma SA
    PhaseRx Inc
    Promethera Biosciences SA
    RaNA Therapeutics Inc
    Selecta Biosciences Inc
    Unicyte AG

    Request for Sample

    Report Url https://www.reportsweb.com//ornithine-transcarbamylase-deficiency-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//ornithine-transcarbamylase-deficiency-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//ornithine-transcarbamylase-deficiency-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments